Connect with us

Science

She Lobbied for Formaldehyde. Now She’s at E.P.A. Approving New Chemicals.

Published

on

She Lobbied for Formaldehyde. Now She’s at E.P.A. Approving New Chemicals.

Formaldehyde, the chemical of choice for undertakers and embalmers, is also used in products like furniture and clothes. But it can also cause cancer and severe respiratory problems. So, in 2021, the Environmental Protection Agency began a new effort to regulate it.

The chemicals industry fought back with an intensity that astonished even seasoned agency officials. Its campaign was led by Lynn Dekleva, then a lobbyist at the American Chemistry Council, an industry group that spends millions of dollars on government lobbying.

Dr. Dekleva is now at the E.P.A. in a crucial job: She runs an office that has the authority to approve new chemicals for use. Earlier she spent 32 years at Dupont, the chemical maker, before joining the E.P.A. in the first Trump administration.

Her most recent employer, the chemicals lobbying group, has made reversing the Environmental Protection Agency’s course on formaldehyde a priority and is pushing to abolish a program under which the agency assess the risks of chemicals to human health. In recent weeks it has urged the agency to discard its work on formaldehyde entirely and start from scratch in assessing the risks.

The American Chemistry Council is also seeking to change the agency’s approval process for new chemicals and speed up E.P.A.’s safety reviews. That review process is a key part of Dr. Dekelva’s purview at the agency.

Advertisement

Another former chemistry council lobbyist, Nancy Beck, is back alongside Dr. Dekleva at the E.P.A. in a role regulating existing chemicals. The council’s president, Chris Jahn, told a Senate hearing shortly after the Trump inauguration that his group intended to tackle the “unnecessary regulation” of chemicals in the United States. “A healthy nation, a secure nation, an economically vibrant nation relies on chemistry,” he said.

It is not unusual or unlawful for industry groups to seek to influence public policy in the interest of their member companies. The A.C.C. estimates that products using formaldehyde support more than 1.5 million jobs in the United States.

What has been extraordinary, health and legal experts said, is the extent of the industry’s effort to block the E.P.A.’s scientific work on a chemical long acknowledged as a carcinogen, and how the architect of the effort was back at the agency as a regulator of chemicals. At the same time, the Trump administration has moved to sharply reduce the federal scientific work force.

“They already have a track record of ignoring the science,” said Tracey Woodruff, director of the Program on Reproductive Health and the Environment at the University of California, San Francisco. “Now, they’re in charge of government agencies that decide the rules.”

While leading the chemistry council’s fight to limit formaldehyde regulation, Dr. Dekleva called for investigations of federal officials for potential bias. The industry group used freedom of information laws to obtain emails of federal employees and criticized them in public statements for what they had written. It submitted dozens of industry-funded research papers to agencies that minimized the risks of formaldehyde.

Advertisement

The A.C.C. also sued both the E.P.A. and the National Academies, which advises the nation on scientific questions, accusing researchers of a lack of scientific integrity.

Allison Edwards, a chemistry council spokeswoman, said officials from the group had regularly met with E.P.A. staff members “to share critical science and to try and ensure an assessment of any chemistry is objective, employs rigorous scientific standards, and is reflective of real-world human exposure.” She said, “We’re asking to be one of many stakeholders at the table.”

Molly Vaseliou, a spokeswoman for the E.P.A., said the agency would continue to make sure it “ensures chemicals do not pose an unreasonable risk to human health or the environment.” At the same time, the agency would also work to approve “chemicals that are needed to power American innovation and competitiveness,” she said.

Formaldehyde’s fumes can cause wheezing and a burning sensation in the eyes, especially when they accumulate indoors. That danger was apparent when formaldehyde in plywood used to build temporary trailer homes for victims of Hurricane Katrina sickened dozens of people.

And there are longer-term dangers, namely several types of cancers. The World Health Organization’s International Agency for Research on Cancer concluded in 2004 that the chemical is a human carcinogen, and the U.S. Department of Health listed it as a human carcinogen in 2011.

Advertisement

The chemical is restricted in the workplace, in certain composite wood products, and in pesticides. Yet efforts to strengthen overall regulations in the United States have stalled in the face of industry opposition.

President Biden, whose “cancer moonshot” program had made reducing cancer deaths a priority, revived in 2021 an E.P.A. assessment of the health effects of the chemical, and published a draft the following year. That effort, under the agency’s Integrated Risk Information System, was the first step toward regulating formaldehyde.

The chemistry council led a coalition of industry groups, including the Composite Panel Association and Kitchen Cabinet Manufacturers, arguing that formaldehyde had already been rigorously studied and that strict industry controls were in place.

In a half-dozen letters to the E.P.A., Dr. Dekleva, on behalf of a formaldehyde panel at the industry group, raised a list of complaints about the way the agency was carrying out its assessment.

She questioned research linking formaldehyde to leukemia, or cancer of the blood, and accused the agency of not relying on the best available science. There was a dose, she said, at which formaldehyde did not cause risk. There was also research, she said, that showed inhaled formaldehyde did not easily travel beyond the nose to cause harm to the body.

Advertisement

In light of these issues, Dr. Dekleva wrote, agency’s draft assessment was “flawed and unreliable without significant revision.”

To bolster its case, the industry group enlisted experts at consulting firms to submit opinions and studies to the E.P.A. minimizing formaldehyde’s risks. The firms included those previously commissioned by tobacco companies to help defend cigarettes.

The A.C.C. also submitted 41 peer-reviewed studies that it said refuted a link between formaldehyde and leukemia. A New York Times review found that the majority of the studies were funded by industry groups, including at least 11 from the Research Foundation for Health and Environmental Effects, an organization established by the American Chemistry Council.

David Michaels, an epidemiologist and professor at George Washington University School of Public Health and assistant secretary of labor under President Barack Obama, said the industry strategy was to create the appearance of disagreement among scientists.

While it’s true, he said, that inconsistencies can always exist in studies on humans, “there’s little disagreement among independent scientists that formaldehyde causes cancer.”

Advertisement

For more than 150 years, the National Academies has advised the U.S. government on science. In 2021, it was asked to weigh in on the E.P.A.’s work on formaldehyde.

It became a target of the American Chemistry Council.

The industry group used freedom of information laws to obtain internal emails of members and support staff of a panel assessing the E.P.A.’s formaldehyde review, and it accused one staff of showing “bias in favor of disputed research claiming formaldehyde causes leukemia.”

The staff member, a former Environmental Protection Agency scientist, had for example described as “wonderful” the news that Congress might try to replicate an influential Chinese study that had shown formaldehyde could cause leukemia.

Wendy E. Wagner, professor at the University of Texas School of Law and an expert on the use of science by environmental policymakers, said she did not see how the comment reflected bias. “After all, they don’t know what the results will be, do they?” she said. “I would expect all scientists to be enthusiastic about potential future research.”

Advertisement

Dr. Dekleva called for investigations at both the E.P.A. and the National Academies, and for the removal of potentially biased panel members and staff. That included scientists who had previously accepted federal research grants.

In July 2023, the industry group sued the E.P.A., as well as the National Academies, accusing researchers of a lack of scientific integrity. The chemistry council said that lack of integrity made the use of the National Academies research in regulating formaldehyde “arbitrary, capricious, and unlawful.”

“It was relentless, and beyond the pale,” said Maria Doa, a scientist at the E.P.A. for 30 years who is now senior director of chemicals policy at the Environmental Defense Fund. “They really ratcheted up their attacks on federal employees.”

The National Academies stood its ground, issuing a report the following month affirming the E.P.A.’s Integrated Risk Information System findings that formaldehyde is carcinogenic and increases leukemia risk.

Those conclusions are shared by other global health authorities.

Advertisement

Mary Schubauer-Berigan, the evidence-synthesis head at the World Health Organization’s Agency for Research on Cancer, said there was “sufficient evidence in humans” that formaldehyde causes leukemia as and nasopharynx cancer. Mikko Vaananen, a spokesman for the European Chemicals Agency, said that while some questions around specific links to leukemia remained unanswered, evidence was sufficient to classify formaldehyde as a carcinogen. Formaldehyde “cannot in principle be placed on the E.U. market,” he said.

In March 2024, a federal judge dismissed the chemistry council’s lawsuit. And early this year, near the end of the Biden administration, the E.P.A. issued a final risk determination, under the Toxic Substances Control Act: Formaldehyde “presents an unreasonable risk of injury to human health.”

Mary A. Fox, an expert in chemical risk assessment at the Johns Hopkins University Bloomberg School of Public Health and a member of a committee that reviewed the E.P.A.’s research on formaldehyde, said agency scientists had accurately reflected the uncertainties around the links between formaldehyde and leukemia. But they had documented many other streams of evidence that indicated that link, Dr. Fox said.

“It’s an inevitable progress of science, that as we learn more over time, we generally learn that health effects appear at lower concentrations than we had thought,” she said.

Following Mr. Trump’s re-election, the American Chemistry Council signed onto a letter from a range of industry groups calling for broad changes to policy, specifically citing formaldehyde. “We urge your administration to pause and reconsider” the E.P.A. findings on formaldehyde, the Dec. 5 letter said.

Advertisement

The E.P.A. “should go back to the scientific drawing board,” chemistry council said in January. The group was particularly concerned about the workplace limits the agency was suggesting, which it said ignored steps companies were already taking to protect workers, like the use of personal protective equipment.

The A.C.C. is also supporting a bill from Republican members of Congress that would end the Integrated Risk Information System.

Soon after, Trump transition officials said Dr. Dekleva would be returning to the E.P.A. to run a program assessing chemicals for approval. The chemistry council, which has long complained of a backlog, is pushing the agency to speed up approvals.

During the first Trump administration, agency whistle-blowers described in an inspector general’s investigation how they had faced “intense” pressure to eliminate the backlog, sometimes at the expense of safety. Shortly after the inauguration, the Trump administration fired the inspector-general who carried out the investigation.

On Jan. 20, the A.C.C. welcomed President Trump. “Americans want a stronger, more affordable country,” said Mr. Jahn, the group’s president. “America’s chemical manufacturers can help.”

Advertisement

Science

In search for autism’s causes, look at genes, not vaccines, researchers say

Published

on

In search for autism’s causes, look at genes, not vaccines, researchers say

Earlier this year, Health and Human Services Secretary Robert F. Kennedy Jr. pledged that the search for autism’s cause — a question that has kept researchers busy for the better part of six decades — would be over in just five months.

“By September, we will know what has caused the autism epidemic, and we’ll be able to eliminate those exposures,” Kennedy told President Trump during a Cabinet meeting in April.

That ambitious deadline has come and gone. But researchers and advocates say that Kennedy’s continued fixation on autism’s origins — and his frequent, inaccurate claims that childhood vaccines are somehow involved — is built on fundamental misunderstandings of the complex neurodevelopmental condition.

Even after more than half a century of research, no one yet knows exactly why some people have autistic traits and others do not, or why autism spectrum disorder looks so different across the people who have it. But a few key themes have emerged.

Researchers believe that autism is most likely the result of a complex set of interactions between genes and the environment that unfold while a child is in the womb. It can be passed down through families, or originate with a spontaneous gene mutation.

Advertisement

Environmental influences may indeed play a role in some autism cases, but their effect is heavily influenced by a person’s genes. There is no evidence for a single trigger that causes autism, and certainly not one a child encounters after birth: not a vaccine, a parenting style or a post-circumcision Tylenol.

“The real reason why it’s complicated, the more fundamental one, is that there’s not a single cause,” said Irva Hertz-Picciotto, a professor of public health science and director of the Environmental Health Sciences Center at UC Davis. “It’s not a single cause from one person to the next, and not a single cause within any one person.”

Kennedy, an attorney who has no medical or scientific training, has called research into autism’s genetics a “dead end.” Autism researchers counter that it’s the only logical place to start.

“If we know nothing else, we know that autism is primarily genetic,” said Joe Buxbaum, a molecular neuroscientist who directs the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai. “And you don’t have to actually have the exact genes [identified] to know that something is genetic.”

Some neurodevelopment disorders arise from a difference in a single gene or chromosome. People with Down syndrome have an extra copy of chromosome 21, for example, and Fragile X syndrome results when the FMR1 gene isn’t expressed.

Advertisement

Autism in most cases is polygenetic, which means that multiple genes are involved, with each contributing a little bit to the overall picture.

Researchers have found hundreds of genes that could be associated with autism; there may be many more among the roughly 20,000 in the human genome.

In the meantime, the strongest evidence that autism is genetic comes from studies of twins and other sibling groups, Buxbaum and other researchers said.

The rate of autism in the U.S. general population is about 2.8%, according to a study published last year in the journal Pediatrics. Among children with at least one autistic sibling, it’s 20.2% — about seven times higher than the general population, the study found.

Twin studies reinforce the point. Both identical and fraternal twins develop in the same womb and are usually raised in similar circumstances in the same household. The difference is genetic: identical twins share 100% of their genetic information, while fraternal twins share about 50% (the same as nontwin siblings).

Advertisement

If one fraternal twin is autistic, the chance that the other twin is also autistic is about 20%, or about the same as it would be for a nontwin sibling.

But if one in a pair of identical twins is autistic, the chance that the other twin is also autistic is significantly higher. Studies have pegged the identical twin concurrence rate anywhere from 60% to 90%, though the intensity of the twins’ autistic traits may differ significantly.

Molecular genetic studies, which look at the genetic information shared between siblings and other blood relatives, have found similar rates of genetic influence on autism, said Dr. John Constantino, a professor of pediatrics, psychiatry and behavioral sciences at the Emory University School of Medicine and chief of behavioral and mental health at Children’s Healthcare of Atlanta.

Together, he said, “those studies have indicated that a vast share of the causation of autism can be traced to the effects of genetic influences. That is a fact.”

Buxbaum compares the heritability of autism to the heritability of height, another polygenic trait.

Advertisement

“There’s not one gene that’s making you taller or shorter,” Buxbaum said. Hundreds of genes play a role in where you land on the height distribution curve. A lot of those genes run in families — it’s not unusual for very tall people, for example, to have very tall relatives.

But parents pass on a random mix of their genes to their children, and height distribution across a group of same-sex siblings can vary widely. Genetic mutations can change the picture. Marfan syndrome, a condition caused by mutations in the FBN1 gene, typically makes people grow taller than average. Hundreds of genetic mutations are associated with dwarfism, which causes shorter stature.

Then once a child is born, external factors such as malnutrition or disease can affect the likelihood that they reach their full height potential.

So genes are important. But the environment — which in developmental science means pretty much anything that isn’t genetics, including parental age, nutrition, air pollution and viruses — can play a major role in how those genes are expressed.

“Genetics does not operate in a vacuum, and at the same time, the impact of the environment on people is going to depend on a person’s individual genetics,” said Brian K. Lee, a professor of epidemiology and biostatistics at Drexel University who studies the genetics of developmental disorders.

Advertisement

Unlike the childhood circumstances that can affect height, the environmental exposures associated with autism for the most part take place in utero.

Researchers have identified multiple factors linked to increased risks of the disorder, including older parental age, infant prematurity and parental exposure to air pollution and industrial solvents.

Investigations into some of these linkages were among the more than 50 autism-related studies whose funding Kennedy has cut since taking office, a ProPublica investigation found. In contrast, no credible study has found links between vaccines and autism — and there have been many.

One move from the Department of Health and Human Services has been met with cautious optimism: even as Kennedy slashed funding to other research projects, the department in September announced a $50-million initiative to explore the interactions of genes and environmental factors in autism, which has been divided among 13 different research groups at U.S. universities, including UCLA and UC San Diego.

The department’s selection of well-established, legitimate research teams was met with relief by many autism scientists.

Advertisement

But many say they fear that such decisions will be an anomaly under Kennedy, who has repeatedly rejected facts that don’t conform to his preferred hypotheses, elevated shoddy science and muddied public health messaging on autism with inaccurate information.

Disagreements are an essential part of scientific inquiry. But the productive ones take place in a universe of shared facts and build on established evidence.

And when determining how to spend limited resources, researchers say, making evidence-based decisions is vital.

“There are two aspects of these decisions: Is it a reasonable expenditure based on what we already know? And if you spend money here, will you be taking money away from HHS that people are in desperate need of?” Constantino said. “If you’re going to be spending money, you want to do that in a way that is not discarding what we already know.”

Advertisement
Continue Reading

Science

Contributor: New mothers are tempted by Ozempic but don’t have the data they need

Published

on

Contributor: New mothers are tempted by Ozempic but don’t have the data they need

My friend Sara, eight weeks after giving birth, left me a tearful voicemail. I’m a clinical psychologist specializing in postpartum depression and psychosis, but mental health wasn’t Sara’s issue. Postpartum weight gain was.

Sara told me she needed help. She’d gained 40 pounds during her pregnancy, and she was still 25 pounds overweight. “I’m going back to work and I can’t look like this,” she said. “I need to take Ozempic or something. But do you know if it’s safe?”

Great question. Unfortunately researchers don’t yet have an answer. On Dec. 1, the World Health Organization released its first guidelines on the use of GLP-1 receptor agonists such as Ozempic, generically known as semaglutide. One of the notable policy suggestions in that report is to not prescribe GLP-1s to pregnant women. Disappointingly, the report says nothing about the use of the drug by postpartum women, including those who are breastfeeding.

There was a recent Danish study that led to medical guidelines against prescribing to patients who are pregnant or breastfeeding.

Advertisement

None of that is what my friend wanted to hear. I could only encourage her to speak to her own medical doctor.

Sara’s not alone. I’ve seen a trend emerging in my practice in which women use GLP-1s to shed postpartum weight. The warp speed “bounce-back” ideal of body shapes for new mothers has reemerged, despite the mental health field’s advocacy to abolish the archaic pressure of martyrdom in motherhood. GLP-1s are being sold and distributed by compound pharmacies like candy. And judging by their popularity, nothing tastes sweeter than skinny feels.

New motherhood can be a stressful time for bodies and minds, but nature has also set us up for incredible growth at that moment. Contrary to the myth of spaced-out “mommy brains,” new neuroplasticity research shows that maternal brains are rewired for immense creativity and problem solving.

How could GLP-1s affect that dynamic? We just don’t know. We do know that these drugs are associated with changes far beyond weight loss, potentially including psychiatric effects such as combating addiction.

Aside from physical effects, this points to an important unanswered research question: What effects, if any, do GLP-1s have on a woman’s brain as it is rewiring to attune to and take care of a newborn? And on a breastfeeding infant? If GLP-1s work on the pleasure center of the brain and your brain is rewiring to feel immense pleasure from a baby coo, I can’t help but wonder if that will be dampened. When a new mom wants a prescription for a GLP-1 to help shed baby weight, her medical provider should emphasize those unknowns.

Advertisement

These drugs may someday be a useful tool for new mothers. GLP-1s are helping many people with conditions other than obesity. A colleague of mine was born with high blood pressure and cholesterol. She exercised every day and adopted a pescatarian diet. Nothing budged until she added a GLP-1 to her regimen, bringing her blood pressure to a healthy 120/80 and getting cholesterol under control. My brother, an otherwise healthy young man recently diagnosed with a rare idiopathic lymphedema of his left leg, is considering GLP-1s to address inflammation and could be given another chance at improving his quality of life.

I hope that GLP-1s will continue to help those who need it. And I urge everyone — especially new moms — to proceed with caution. A healthy appetite for nutritious food is natural. That food fuels us for walks with our dogs, swims along a coastline, climbs through leafy woods. It models health and balance for the young ones who are watching us for clues about how to live a healthy life.

Nicole Amoyal Pensak, a clinical psychologist and researcher, is the author of “Rattled: How to Calm New Mom Anxiety With the Power of the Postpartum Brain.”

Advertisement
Continue Reading

Science

California issues advisory on a parasitic fly whose maggots can infest living humans

Published

on

California issues advisory on a parasitic fly whose maggots can infest living humans

A parasitic fly whose maggots can infest living livestock, birds, pets and humans could threaten California soon.

The New World Screwworm has rapidly spread northward from Panama since 2023 and farther into Central America. As of early September, the parasitic fly was present in seven states in southern Mexico, where 720 humans have been infested and six of them have died. More than 111,000 animals also have been infested, health officials said.

In early August, a person traveling from El Salvador to Maryland was discovered to have been infested, federal officials said. But the parasitic fly has not been found in the wild within a 20-mile radius of the infested person, which includes Maryland, Virginia and the District of Columbia.

After the Maryland incident, the California Department of Public Health decided to issue a health advisory this month warning that the New World Screwworm could arrive in California from an infested traveler or animal, or from the natural travel of the flies.

Advertisement

Graphic images of New World Screwworm infestations show open wounds in cows, deer, pigs, chickens, horses and goats, infesting a wide swath of the body from the neck, head and mouth to the belly and legs.

The Latin species name of the fly — hominivorax — loosely translates to “maneater.”

“People have to be aware of it,” said Dr. Peter Chin-Hong, a UC San Francisco infectious diseases specialist. “As the New World Screwworm flies northward, they may start to see people at the borders — through the cattle industry — get them, too.”

Other people at higher risk include those living in rural areas where there’s an outbreak, anyone with open sores or wounds, those who are immunocompromised, the very young and very old, and people who are malnourished, the U.S. Centers for Disease Control and Prevention says.

There could be grave economic consequences should the New World Screwworm get out of hand among U.S. livestock, leading to animal deaths, decreased livestock production, and decreased availability of manure and draught animals, according to the U.S. Department of Agriculture.

Advertisement

“It is not only a threat to our ranching community — but it is a threat to our food supply and our national security,” the USDA said.

Already, in May, the USDA suspended imports of live cattle, horse and bison from the Mexican border because of the parasitic fly’s spread through southern Mexico.

The New World Screwworm isn’t new to the U.S.

But it was considered eradicated in the United States in 1966, and by 1996, the economic benefit of that eradication was estimated at nearly $800 million, “with an estimated $2.8 billion benefit to the wider economy,” the USDA said.

Texas suffered an outbreak in 1976. A repeat could cost the state’s livestock producers $732 million a year and the state economy $1.8 billion, the USDA said.

Advertisement

Historically, the New World Screwworm was a problem in the U.S. Southwest and expanded to the Southeast in the 1930s after a shipment of infested animals, the USDA said. Scientists in the 1950s discovered a technique that uses radiation to sterilize male parasitic flies.

Female flies that mate with the sterile male flies produce sterile eggs, “so they can’t propagate anymore,” Chin-Hong said. It was this technique that allowed the U.S., Mexico and Central America to eradicate the New World Screwworm by the 1960s.

But the parasitic fly has remained endemic in South America, Cuba, Haiti and the Dominican Republic.

In late August, the USDA said it would invest in new technology to try to accelerate the pace of sterile fly production. The agency also said it would build a sterile-fly production facility at Edinburg, Texas, which is close to the Mexico border, and would be able to produce up to 300 million sterile flies per week.

“This will be the only United States-based sterile fly facility and will work in tandem with facilities in Panama and Mexico to help eradicate the pest and protect American agriculture,” the USDA said.

Advertisement

The USDA is already releasing sterile flies in southern Mexico and Central America.

The risk to humans from the fly, particularly in the U.S., is relatively low. “We have decent nutrition; people have access to medical care,” Chin-Hong said.

But infestations can happen. Open wounds are a danger, and mucus membranes can also be infested, such as inside the nose, according to the CDC.

An infestation occurs when fly maggots infest the living flesh of warm-blooded animals, the CDC says. The flies “land on the eyes or the nose or the mouth,” Chin-Hong said, or, according to the CDC, in an opening such as the genitals or a wound as small as an insect bite. A single female fly can lay 200 to 300 eggs at a time.

When they hatch, the maggots — which are called screwworms — “have these little sharp teeth or hooks in their mouths, and they chomp away at the flesh and burrow,” Chin-Hong said. After feeding for about seven days, a maggot will fall to the ground, dig into the soil and then awaken as an adult fly.

Advertisement

Deaths among humans are uncommon but can happen, Chin-Hong said. Infestation should be treated as soon as possible. Symptoms can include painful skin sores or wounds that may not heal, the feeling of the larvae moving, or a foul-smelling odor, the CDC says.

Patients are treated by removal of the maggots, which need to be killed by putting them into a sealed container of concentrated ethyl or isopropyl alcohol then disposed of as biohazardous waste.

The parasitic fly has been found recently in seven Mexican states: Campeche, Chiapas, Oaxaca, Quintana Roo, Tabasco, Veracruz, and Yucatán. Officials urge travelers to keep open wounds clean and covered, avoid insect bites, and wear hats, loose-fitting long-sleeved shirts and pants, socks, and insect repellents registered by the Environmental Protection Agency as effective.

Advertisement
Continue Reading

Trending